Question explored with the scientific record
what is naltrexone for/do?
Naltrexone is a real drug with real trial evidence, but only for a narrow job: blocking the opioid reward that drives heavy drinking and opioid use.
Naltrexone is an opioid blocker. It sits on the mu-opioid receptor and blocks the body's own endorphins from reinforcing the pleasure of a drink or a hit [3]. That is the whole mechanism. It does not make you sick if you drink, and it does not treat withdrawal. It removes some of the reward.
For alcohol, the trials are decent. A meta-analysis of randomized trials found relapse reduced and abstinence increased versus placebo [1]. In a 131-person double-blind trial, 62% on naltrexone stayed relapse-free versus 40% on placebo, and drinks per drinking day fell from 4.2 to 2.5 [2]. Side effects were real: nausea 34% vs 14%, sleepiness 46% vs 27% [2]. Craving drops faster on it [4].
| Outcome | Naltrexone | Placebo |
|---|---|---|
| Relapse-free at 12 weeks | 62% | 40% |
| Drinks per drinking day | 2.5 | 4.2 |
| Nausea | 34% | 14% |
| Daytime sleepiness | 46% | 27% |
For opioid use disorder it is used as a monthly injection, and adherence is the weak point: in one veteran cohort, monthly adherence fell to about 25% by six months [5]. It also has an off-label use in pathological gambling, where a small high-dose trial showed improvement but with liver enzyme rises in some patients [6].
What this retrieval cannot see: long-term outcomes past a year, and head-to-head data against therapy alone. The trials above are mostly short and industry-adjacent.
My call: worth trying for alcohol use disorder if you can tolerate the nausea, with modest expectations. Confidence: moderate for short-term drinking reduction, low for anything long-term.
Sources used 6
-
NALTREXONE, A RELAPSE PREVENTION MAINTENANCE TREATMENT OF ALCOHOL DEPENDENCE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
This meta-analysis evaluates the efficacy and safety of naltrexone as a treatment for alcohol dependence, demonstrating that it significantly reduces relapse rates and increases abstinence compared to placebo.
DOI: 10.1093/alcalc/36.6.544 -
Naltrexone and Cognitive Behavioral Therapy for the Treatment of Outpatient Alcoholics: Results of a Placebo-Controlled Trial
A randomized, double-blind, 12-week trial in 131 outpatient alcohol-dependent adults found that adding 50 mg/day naltrexone to manual-guided cognitive behavioral therapy reduced relapse, increased time to relapse and days abstinent, and lowered drinks per drinking day versus pla…
DOI: 10.1176/AJP.156.11.1758 -
Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
A comprehensive review of pharmacological treatments for alcohol dependence, outlining the first, second, and emerging third waves of drug targets, the relapse-related mechanisms they aim to modulate, supporting preclinical models, and the promise of personalized approaches guid…
DOI: 10.1016/j.pharmthera.2006.02.001 -
Reductions in Alcohol Craving Following Naltrexone Treatment for Heavy Drinking
This study investigates the effects of naltrexone on alcohol craving in alcohol-dependent patients, finding that those treated with naltrexone experienced a more rapid decrease in craving compared to a matched control group not receiving the medication.
DOI: 10.1093/alcalc/agw038 -
Adherence to extended release naltrexone: Patient and treatment characteristics
Over 12 months, XR-NTX adherence in veterans with AUD or OUD did not differ by primary drug of choice and was positively associated with concurrent psychosocial therapies, with an average of five injections observed.
DOI: 10.1111/ajad.12786 -
Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling
This randomized, double-blind trial assessed high-dose naltrexone versus placebo in adults with DSM-IV pathologic gambling, finding significant improvements in gambling symptoms and global outcomes with naltrexone, albeit with notable hepatic enzyme elevations linked to analgesi…
DOI: 10.1016/s0006-3223(01)01079-4